Voices
A New FDA Approval is Changing Treatment Options in HR+/HER2+ Metastatic Breast Cancer – BCRF

A New FDA Approval is Changing Treatment Options in HR+/HER2+ Metastatic Breast Cancer – BCRF

The Breast Cancer Research Foundation shared a post on LinkedIn:

“A new FDA approval is changing treatment options for people with HR+/HER2+ metastatic breast cancer.

Backed by findings from the BCRF-supported PATINA clinical trial, adding Ibrance to standard treatment helped patients live longer without their cancer progressing and delayed treatment resistance.

Swipe to learn what this approval means for patients, and learn more about the latest therapies for HR+/HER2+ breast cancer.”

A New FDA Approval is Changing Treatment Options in HR+/HER2+ Metastatic Breast Cancer - BCRF

You can also read:

FDA Approves Palbociclib-Based Maintenance Therapy for HR-Positive, HER2-Positive Metastatic Breast Cancer
A New FDA Approval is Changing Treatment Options in HR+/HER2+ Metastatic Breast Cancer - BCRF

Breast Cancer cancer FDA OncoDaily Oncology PATINA trial The Breast Cancer Research Foundation